Highest-materiality recent filing
Tandem Diabetes shareholders approve charter amendments and equity plan increase at annual meeting
Shareholders approved charter amendments to allow removal of directors with or without cause and limit officer liability per DGCL Sections 141(k) and 102(b)(7).
Tandem Diabetes terminates CCO Mark Novara without cause; last day May 18
Mark Novara, EVP & Chief Commercial Officer, notified of termination without cause on May 11, 2026.
Earnings release filed; exhibit not provided in context
Tandem Diabetes Care filed 8-K for Q1 2026 earnings.
Tandem Diabetes closes $300M zero-coupon convertible notes due 2032; net proceeds ~$290.7M
Issued $300M aggregate principal of 0.00% Convertible Senior Notes due 2032 (including $35M greenshoe exercised).
Tandem Diabetes issues Q4/FY2025 earnings release; specific results not provided in filing excerpt
Filing reports issuance of press release for quarter and year ended 12/31/2025.
Tandem Diabetes amends bylaws with updated advance notice, proxy card, voting rules
Board adopted Amended and Restated Bylaws on Dec 26, 2025 as part of periodic governance review.
Tandem Diabetes appoints Sandra Beaver to board, adds audit and cybersecurity roles
Sandra Beaver joined the board effective Nov. 7, 2025, increasing board size from 8 to 9.
Earnings press release for quarter ended September 30, 2025 was furnished as Exhibit 99.1.
Tandem Diabetes receives FDA 510(k) clearance for SteadiSet infusion set for 7-day use
FDA cleared SteadiSet infusion set for up to seven days of use; features integrated inserter with hidden needle.
Q2 2025 earnings release furnished; no specific figures provided in filing text
Press release dated June 30, 2025, furnished as Exhibit 99.1, but content not included in the provided filing text.
Tandem settles patent disputes with Roche, agrees to pay $36M over five years
Settlement resolves pending patent actions in France and Germany regarding t:slim X2 pump and two EP patents.
CE mark granted for Tandem Mobi insulin delivery system with Control-IQ+ technology.
FDA cleared SteadiSet infusion set for up to 3 days of use; submission by subsidiary CapBio.
Tandem Diabetes Care files Q1 2025 results; no financial details in filing excerpt
8-K filed April 30, 2025 announcing Q1 2025 financial results.
Tandem Diabetes Care releases Q4/FY2024 earnings; financial figures not provided in filing excerpt
Company issued press release on February 26, 2025 for Q4 and full year 2024 results.
Tandem Diabetes reports Q3 2024 results; no details in furnished text
Filing states a press release was issued for Q3 ended September 30, 2024.
Tandem Diabetes Care reports Q2 2024 results via press release (exhibit text not provided)
Filed 8-K indicating a press release was issued on Aug 1, 2024 for Q2 ended June 30, 2024.
Tandem Diabetes appoints Jean-Claude Kyrillos as EVP, COO effective June 21, 2024
Kyrillos previously served as President of Diagnostics & Digital Solutions at Envista Holdings and held senior roles at Qualcomm Life, BD, and ResMed.
Tandem and Dexcom amend agreements to integrate Sigi pump with G7 CGM for five years
On May 22, 2024, Tandem and Dexcom entered into two amended and restated agreements.
Tandem Diabetes stockholders approve 3M-share increases to ESPP and LTIP at annual meeting
Stockholders elected all 9 director nominees; highest vote count for John Sheridan (50.3M for).
Tandem obtains Health Canada approval for Trurapi U-100 compatibility with t:slim X2 pump
Health Canada approved adding Trurapi U-100 to compatible insulins list for t:slim X2 with Control-IQ in Canada.
Tandem Diabetes Care reports Q1 2024 results; specific figures not provided in filing text
Press release dated May 2, 2024 covers quarter ended March 31, 2024.
FDA clears Tandem Mobi insulin pump for pediatric use ages 2+
FDA cleared Tandem Mobi insulin pump for expanded pediatric indication in individuals two years and older.
Issued $316.25M aggregate principal amount of 1.50% Convertible Senior Notes due 2029, including full exercise of initial purchasers' option for additional $41.25M.
Tandem Diabetes reports Q4/FY2023 results; detailed metrics not available in filing text
Press release furnished as Exhibit 99.1 contains financial results for quarter and year ended Dec 31, 2023.
COO David Berger steps down Dec 31; transitions to part-time advisor through 2024
Berger resigns as EVP & COO effective Dec 31, 2023; no successor named.
Tandem Diabetes COO David Berger to step down Dec 31, 2023
David B. Berger, EVP and COO, will leave his role effective December 31, 2023.
Tandem Diabetes receives FDA clearance for t:slim X2 pump and Control-IQ for children 2+
FDA cleared 510(k) applications for t:slim X2 insulin pump and Control-IQ technology enhancements on Nov 3, 2023.
Tandem Diabetes Care files 8-K for Q3 2023 earnings; no financial figures in filing
Company issued a press release reporting results for quarter ended September 30, 2023.
Tandem CCO Brian Hansen resigns, to stay on leave through June 2024
Brian Hansen resigns as EVP & CCO effective Dec 31, 2023; remains employed through June 28, 2024 on paid administrative leave.
Tandem Diabetes Care announces Q2 2023 results; detailed figures unavailable from excerpt
Company issued press release on August 3, 2023 for quarter ended June 30, 2023.
Tandem Diabetes annual meeting results: all director nominees elected, 2023 LTIP approved
Stockholders elected 7 directors; Blickenstaff, Cha, Howell, Malagueira, McGroddy-Goetz, Sheridan, Twomey.
Tandem Diabetes Q1 revenue $186M, up 14% YoY; net loss $(49.1M)
Revenue $186.0M (+14% YoY); GAAP net loss $(49.1M) or $(0.75) per share.
Kim Blickenstaff steps down as Chair but remains a board member; served as Chair since March 2020.
Tandem Diabetes completes acquisition of AMF Medical for CHF 70.4M upfront plus earnouts
Total upfront consideration: CHF 8.0M strategic investment (Q3 2022) plus CHF 62.4M cash at closing.
Press release contains unaudited preliminary Q4 and full-year 2022 results.
Tandem Diabetes Care to acquire AMF Medical (Sigi Patch Pump) for up to CHF 200M
Cash payment of CHF 62.4M at closing plus CHF 8M prior strategic investment; earnouts up to CHF 129.6M.
Tandem Diabetes reports Q3 2022 results; financial details unavailable from filing excerpt
Tandem Diabetes issued a press release on November 2, 2022, covering Q3 2022 financial performance.
Tandem Diabetes Care reports Q2 2022 earnings; specific figures not in filing text
Press release for Q2 ended June 30, 2022 furnished as Exhibit 99.1 but not reproduced in provided text.
Tandem Diabetes appoints Myoung Cha and Joao Malagueira to board
Myoung Cha elected Class III director effective June 15, 2022; will serve on Compensation Committee.
Tandem Diabetes shareholders elect directors, approve board declassification and say-on-pay
Peyton R. Howell and John F. Sheridan elected as Class III directors with ~98.6% and ~98.1% of votes cast.
Tandem Diabetes Care reports Q1 2022 earnings; no specifics in filing
Announced financial results for the quarter ended March 31, 2022 on May 4, 2022.
Director Douglas A. Roeder not standing for re-election at Tandem's 2022 Annual Meeting
Douglas A. Roeder notified the company on March 11, 2022, of his decision not to stand for re-election.
Tandem Diabetes Q4 sales $210M (+25% YoY); FY2021 sales $703M (+41%); 2022 guide $845-860M
Full-year 2021 sales $702.8M (+41% YoY); net income $15.6M vs loss $34.4M in 2020.
FDA clears Tandem Diabetes t:slim X2 insulin pump to deliver bolus via smartphone app
FDA cleared t:slim X2 insulin pump to program and cancel bolus insulin doses using t:connect mobile app on iOS and Android.
Tandem Diabetes Q3 sales $179.6M (+45% YoY); raises FY2021 sales guidance to $685-695M
Q3 sales $179.6M (+45% YoY); net income $5.8M vs loss $9.4M; adjusted EBITDA $26.9M (15% of sales).
Tandem Diabetes signs lease for 181,949 sq ft in San Diego; total future rent ~$192M
Lease with Kilroy Realty for 181,949 sq ft at 12400 High Bluff Drive, San Diego, in two phases.
Tandem Diabetes reports Q2 2021 earnings; specific figures not available in filing text
Press release filed as Exhibit 99.1 but text not provided; no financial data extractable.
On May 11, 2026, Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the “Company”), was notified that his employment with the Company is being terminated without cause.
On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.
on November 7, 2023, the Company and David B. Berger, the Company’s Executive Vice President and Chief Operating Officer, determined that Mr. Berger will be stepping down from his current position effective December 31, 2023.
On November 7, 2023, Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) and David B. Berger, the Company’s Executive Vice President and Chief Operating Officer, determined that he will be stepping down from his current position effective December 31, 2023.
On August 17, 2023, Brian B. Hansen, Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the Company), notified the Company of his decision to resign from his role as Executive Vice President and Chief Commercial Officer, effective December 31, 2023.
Rebecca Robertson will succeed Kim D. Blickenstaff as Chair of the Board of Directors (the “Board”), effective March 1, 2023.
Mr. Allen will transition from the role of Lead Independent Director to a member of the Board.
Mr. Blickenstaff will transition from the role of Chair of the Board to a member of the Board
elected Joao Malagueira, age 56, to serve as a Class I director on the Board
elected Myoung Cha, age 45, to serve as a Class III director on the Board
On March 11, 2022, Douglas A. Roeder, notified the Company of his decision not to stand for re-election at the Company’s 2022 Annual Meeting of Stockholders
On February 3, 2022, the Board of Directors appointed David B. Berger, age 52, to serve as the Company’s Executive Vice President, Chief Operating Officer and Assistant Secretary.
Max materiality 0.80 · Median 0.50 · Most common event earnings